Skip to main
NGNE

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene Inc. is showing promise in its clinical-stage developments, particularly with NGN-401 for Rett syndrome, which has demonstrated durable improvements over 24 months in multiple clinical domains, outperforming peer data metrics. The company has significantly expanded its U.S. clinical footprint to 13 sites, enhancing its capacity for rapid patient enrollment while aligning with industry peers, indicating strong demand and support among caregivers. Moreover, the proprietary EXACTTM platform demonstrates a substantial advantage in brain expression compared to alternative technologies, underscoring Neurogene's competitive positioning in the biotechnology sector focused on rare neurological diseases.

Bears say

Neurogene Inc faces significant risks that could hinder its clinical development efforts and negatively impact its stock performance. Key concerns include potential delays in advancing its drug candidates through the clinical assessment process, specifically for NGN-401 in treating Rett syndrome, and the uncertainty surrounding the generation of favorable clinical data. Additionally, there is an underlying risk of long-term dilution and potential competitive disadvantages due to the anticipated need for amending regulatory filings based on delayed or inconclusive clinical results.

Neurogene Inc (NGNE) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Buy based on their latest research and market trends.

According to 5 analysts, Neurogene Inc (NGNE) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.